Bio-Path Holdings, Inc. (NASDAQ:BPTH – Get Rating) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.62 and traded as high as $1.74. Bio-Path shares last traded at $1.71, with a volume of 30,799 shares.
Analyst Ratings Changes
A number of research analysts recently weighed in on the stock. Roth Capital reiterated a “buy” rating on shares of Bio-Path in a research note on Friday, March 17th. StockNews.com assumed coverage on Bio-Path in a report on Wednesday. They set a “sell” rating on the stock.
Bio-Path Stock Up 2.4 %
The business’s 50-day moving average price is $1.48 and its 200 day moving average price is $1.62. The company has a market capitalization of $13.61 million, a P/E ratio of -0.81 and a beta of 1.30.
Institutional Investors Weigh In On Bio-Path
Several hedge funds have recently bought and sold shares of BPTH. Mount Yale Investment Advisors LLC bought a new stake in Bio-Path during the third quarter worth about $81,000. Renaissance Technologies LLC bought a new stake in shares of Bio-Path in the 2nd quarter worth approximately $70,000. Virtu Financial LLC purchased a new stake in shares of Bio-Path in the 1st quarter valued at $38,000. Finally, Citadel Advisors LLC bought a new position in shares of Bio-Path during the 3rd quarter valued at $35,000. 6.42% of the stock is currently owned by institutional investors.
Bio-Path Holdings, Inc is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.
- Get a free copy of the StockNews.com research report on Bio-Path (BPTH)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.